# FDA Requests More Safety Data for Foundayo, Oral GLP-1 Drug
The FDA has asked for additional safety information before approving Foundayo, an oral pill version of GLP-1 weight loss medication. This request delays what could have been the first pill-based alternative to injectable drugs like Wegovy and Ozempic.
Foundayo, developed by Viking Therapeutics, works similarly to existing GLP-1 drugs by mimicking a hormone that regulates appetite and blood sugar. The oral formulation appeals to patients who prefer pills over injections. However, the FDA determined the current data package doesn't fully address long-term safety concerns needed for approval.
The agency's request doesn't mean Foundayo fails to work. Rather, regulators want more comprehensive information about how the drug performs over extended use and in diverse patient populations. This is standard procedure for medications targeting weight management and metabolic health.
Parents and adults considering weight loss options should understand the regulatory timeline. Foundayo won't reach pharmacy shelves immediately. The additional data collection could take months or years, depending on what the FDA specifically requires and how quickly Viking Therapeutics completes the studies.
Current GLP-1 options remain available through injections. Wegovy (semaglutide) and Saxenda (liraglutide) have established safety profiles from extensive clinical trials. These remain the standard treatment when medically appropriate.
The FDA's caution reflects appropriate oversight. GLP-1 drugs carry known side effects including nausea, vomiting, and rare but serious pancreatitis concerns. Patients must receive complete information before choosing any weight loss medication.
For families managing weight, consult your doctor about existing options. Discuss whether GLP-1 therapy aligns with your situation, the injection or potential future pill form, and realistic expectations. Weight